Lyon manufacturing facility returns to the Vectura Group
The facility currently manufactures seven oral products for the Group's partners.
Vectura Group has confirmed that, as expected, the lease of its manufacturing facility and oral product business in Saint-Quentin-Fallavier, Lyon, France to Aenova France expired on 30 June 2016. The facility transferred back to the Group upon expiry.
The facility currently manufactures seven oral products for the Group's partners. Five products use the Geomatrix family of technologies: Diclofenac-ratiopharm-uno, Coruno, ZYFLO CR, Madopar DR/Prolopa and Sular, whilst Lodotra/RAYOS uses the Geoclock chronotechnology. The facility also manufactures one other oral product, Triglide, based on the Group's solubilisation technology. In addition, there are currently a number of pipeline projects in development, including the first complex oral generic under the Group's strategic partnership with Hikma Pharmaceuticals. The facility has cGMP status, with approvals from the European Medicines Agency, the FDA, ANVISA (Brazil) and KFDA (South Korea) amongst others.
A number of initiatives are underway to maximise the value of the facility now that it has returned to the Group's control, leveraging proven capabilities in multilayer tableting, oral technology innovation and the high quality manufacturing capacity at the Lyon site.
David Lescuyer, Executive Vice President, Oral Business, commented: "We are very pleased that the Lyon facility returns to the Group at this exciting time. We have a strong high quality base with the return of the facility and we are confident of growing the business and creating future value by working with existing and new partners and leveraging our proven innovation and technology."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance